<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Gal3 on Agnès Pérez-Millan</title>
    <link>https://Agnes2.github.io/tags/gal3/</link>
    <description>Recent content in Gal3 on Agnès Pérez-Millan</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Nov 2023 00:00:00 +0000</lastBuildDate><atom:link href="https://Agnes2.github.io/tags/gal3/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity</title>
      <link>https://Agnes2.github.io/publications/2023-gal3/</link>
      <pubDate>Wed, 29 Nov 2023 00:00:00 +0000</pubDate>
      
      <guid>https://Agnes2.github.io/publications/2023-gal3/</guid>
      <description>Sergi Borrego-Écija*, Agnès Pérez-Millan*, Anna Antonell, Laura Fort-Aznar, Elif Kaya-Tilki, Alberto León-Halcón, Albert Lladó, Laura Molina-Porcel, Mircea Balasa, Jordi Juncà-Parella, Javier Vitorica, Jose Luis Venero, Tomas Deierborg, Antonio Boza-Serrano, Raquel Sánchez-Valle. (* equivalent contribution). Alzheimer&amp;rsquo;s &amp;amp; Dementia.
ABSTRACT
INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate Gal-3 levels in patients with FTD and assess its diagnostic potential.</description>
    </item>
    
  </channel>
</rss>
